Leerink Partnrs Research Analysts Reduce Earnings Estimates for Lantheus Holdings, Inc. (NASDAQ:LNTH)

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Equities research analysts at Leerink Partnrs cut their Q1 2024 earnings per share estimates for Lantheus in a research note issued on Wednesday, April 17th. Leerink Partnrs analyst R. Ruiz now anticipates that the medical equipment provider will post earnings per share of $1.47 for the quarter, down from their previous forecast of $1.48. The consensus estimate for Lantheus’ current full-year earnings is $5.72 per share. Leerink Partnrs also issued estimates for Lantheus’ Q2 2024 earnings at $1.49 EPS, FY2024 earnings at $5.92 EPS and FY2025 earnings at $5.49 EPS.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, topping analysts’ consensus estimates of $1.33 by $0.26. The business had revenue of $354.00 million for the quarter, compared to analyst estimates of $350.44 million. Lantheus had a return on equity of 63.16% and a net margin of 25.20%.

Several other equities analysts have also issued reports on LNTH. B. Riley boosted their price target on Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a research note on Thursday. JMP Securities reaffirmed a “market outperform” rating and set a $100.00 price objective on shares of Lantheus in a report on Friday, February 23rd. StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a report on Saturday, January 13th. Finally, Truist Financial reaffirmed a “buy” rating and set a $82.00 price objective (up from $80.00) on shares of Lantheus in a report on Monday, February 26th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $104.71.

Lantheus Trading Up 1.4 %

Shares of LNTH opened at $62.33 on Friday. Lantheus has a 12-month low of $50.20 and a 12-month high of $100.85. The company has a quick ratio of 5.45, a current ratio of 5.80 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $4.27 billion, a price-to-earnings ratio of 13.43 and a beta of 0.53. The stock’s 50-day moving average price is $60.66 and its 200 day moving average price is $62.99.

Hedge Funds Weigh In On Lantheus

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC increased its holdings in Lantheus by 198.2% during the 3rd quarter. FMR LLC now owns 2,146,085 shares of the medical equipment provider’s stock worth $149,110,000 after purchasing an additional 1,426,465 shares in the last quarter. Vanguard Group Inc. increased its holdings in Lantheus by 32.9% during the 1st quarter. Vanguard Group Inc. now owns 5,742,083 shares of the medical equipment provider’s stock worth $317,595,000 after purchasing an additional 1,422,269 shares in the last quarter. Norges Bank bought a new position in Lantheus during the 4th quarter worth about $45,379,000. Point72 Asset Management L.P. bought a new position in Lantheus during the 4th quarter worth about $28,042,000. Finally, Alliancebernstein L.P. increased its holdings in Lantheus by 18.1% during the 4th quarter. Alliancebernstein L.P. now owns 3,193,302 shares of the medical equipment provider’s stock worth $162,731,000 after purchasing an additional 489,203 shares in the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Lantheus

In related news, Director Mary Anne Heino sold 93,863 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the sale, the director now owns 251,643 shares in the company, valued at approximately $16,434,804.33. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the stock in a transaction that occurred on Wednesday, March 6th. The stock was acquired at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the transaction, the insider now directly owns 116,773,394 shares in the company, valued at $110,934,724.30. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mary Anne Heino sold 93,863 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the completion of the sale, the director now owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The disclosure for this sale can be found here. In the last 90 days, insiders sold 94,545 shares of company stock worth $6,169,936. Insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.